Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer.
- Author:
In Sil CHOI
1
;
Do Youn OH
;
Byoung Su KIM
;
Keun Wook LEE
;
Jee Hyun KIM
;
Jong Seok LEE
Author Information
1. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. jhkimmd@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Stomach neoplasms;
Elderly;
Chemotherapy;
Oxaliplatin
- MeSH:
Aged*;
Anemia;
Drug Therapy*;
Febrile Neutropenia;
Fluorouracil*;
Humans;
Leucovorin*;
Neutropenia;
Peripheral Nervous System Diseases;
Stomach Neoplasms*
- From:Cancer Research and Treatment
2007;39(3):99-103
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We investigated the efficacy and safety of a combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line palliative chemotherapy for elderly patients with metastatic or recurrent gastric cancer. MATERIALS AND METHODS: The study patients were chemotherapy-naive patients (> 65 years old) with histologically confirmed, metastatic or recurrent gastric cancer. Chemotherapy consisted of oxaliplatin 100 mg/m2 and FA 100 mg/m2 (2-hour infusion), and then 5-FU 2400 mg/m2 (46-hour continuous infusion) every 2 weeks. RESULTS: A total of 37 patients were studied between April 2004 and October 2006. Of the 34 evaluable patients, none achieved a complete response (CR) and 14 achieved a partial response (PR), resulting in an overall response rate of 41.2%. The median time to progression (TTP) was 5.7 months (95% CI: 4.2~6.3 months) and the median overall survival (OS) was 9.8 months (95% CI: 4.4~12.0 months). The main hematologic toxicities were anemia and neutropenia, which were observed in 56.7% and 32.4% of the patients, respectively. Grade 3/4 neutropenia was observed in 8.1% of the patients. None of the patients experienced febrile neutropenia. Peripheral neuropathy occurred in 35.1% of the patients and all were grade 1/2. CONCLUSION: This oxaliplatin/5-FU/FA regimen showed good efficacy and an acceptable toxicity profile in elderly patients with metastatic or recurrent gastric cancer.
